Live Feeds
● LIVE Updated 1h ago · 11 sources tracked

Roche returns to China’s ADC powerhouse Hansoh for $15B biobucks pact

Pharmaceutical giant Roche has struck a massive agreement with China-based Hansoh Pharmaceutical to develop a portfolio of antibody-drug conjugates. The partnership includes an upfront payment of $400 million and more than $15 billion in potential biobucks and milestone payments. Roche will secure ex-China development rights for two of Hansoh's preclinical antibody-drug conjugates, alongside multiple programs directed at targets proposed by Roche. The collaboration marks a significant expansion of the existing alliance between the two companies, leveraging Hansoh's proprietary in-house technology.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (11)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Roche is paying Hansoh Pharmaceutical $400 million upfront in a broad deal involving several antibody-drug conjugates.
  • ✓ The total value of the deal could exceed $15 billion in potential biobucks and milestone payments.
  • ✓ Roche will take ex-China development of Hansoh's two preclinical antibody-drug conjugates and multiple programs against Roche-proposed targets after Hansoh completes global phase 1a trials.
🛡️ Source Corroboration: 11 independent reporting domains (100% confidence) ⏱ Read time: ~2 min

What changed

Roche and Hansoh signed a second antibody-drug conjugate pact worth over $15 billion in potential biobucks, anchored by a $400 million upfront payment.

Live updates

  1. Roche and Hansoh Ink $15B ADC Partnership

    Pharmaceutical giant Roche has struck a massive agreement with China-based Hansoh Pharmaceutical to develop a portfolio of antibody-drug conjugates. The partnership includes an upfront payment of $400 million and more than $15 billion in potential biobucks and milestone payments. Roche will secure ex-China development rights for two of Hansoh's preclinical antibody-drug conjugates, alongside multiple programs directed at targets proposed by Roche. The collaboration marks a significant expansion of the existing alliance between the two companies, leveraging Hansoh's proprietary in-house technology.

    Why it matters

    This agreement underscores the growing trend of Western pharmaceutical companies partnering with Chinese drug developers to access advanced oncology pipelines, particularly in the competitive space of antibody-drug conjugates. Hansoh brings extensive R&D experience and a robust pipeline spanning oncology, metabolism, and immunology to the collaboration. The scale of the upfront and milestone payments reflects high industry confidence in Hansoh's proprietary platforms.

    What is confirmed

    • Roche is paying Hansoh Pharmaceutical $400 million upfront in a broad deal involving several antibody-drug conjugates.
    • The total value of the deal could exceed $15 billion in potential biobucks and milestone payments.
    • Roche will take ex-China development of Hansoh's two preclinical antibody-drug conjugates and multiple programs against Roche-proposed targets after Hansoh completes global phase 1a trials.

    Still unconfirmed

    • The agreement includes a payment of $110 million on its first anniversary in addition to other contingent milestones.

    What to watch next

    • Completion of global phase 1a trials by Hansoh for the two preclinical antibody-drug conjugates
    • Progress on Roche-proposed targets under the expanded alliance
    Sources used for this update (11)
    1. www.myasset.com — Sector News & Data
    2. Fierce Biotech — Roche returns to China’s ADC powerhouse Hansoh for $15B biobucks pact
    3. Reuters — China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion
    4. WSJ — Roche Partners With China’s Hansoh in Deal That Could Top $15 Billion
    5. FirstWord Pharma — Roche, Hansoh expand ADC alliance in deal with $15B-plus potential
    6. Endpoints News — Roche does $400M upfront, $15B deal with China’s Hansoh
    7. www.biospace.com — Roche returns to Hansoh with broad $15B ADC deal - BioSpace
    8. www.biopharminternational.com — Roche, Hansoh Sign Second ADC Pact Covering Preclinical and ...
    9. www.hspharm.com — HANSOH PHARMA ANNOUNCES STRATEGIC COLLABORATION AND LICENSE ...
    10. finance.yahoo.com — Roche inks $15B ADC pact with Hansoh; Veradermics scores in ...
    11. lifesciencedaily.news — Roche Hansoh ADC Deal: What $400 Million Buys Roche
    confidence 100%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community